How much did Mayne Pharma Group achieve in EBIT for the current year?
In the current year, Mayne Pharma Group has achieved an EBIT of -47.13 M AUD.
Mayne Pharma Group EBIT 2024
Mayne Pharma Group EBIT
-47.13 M AUD
Ticker
MYX.AX
ISIN
AU000000MYX0
WKN
A1C821
In 2024, Mayne Pharma Group's EBIT was -47.13 M AUD, a -71.52% increase from the -165.45 M AUD EBIT recorded in the previous year.
The Mayne Pharma Group EBIT history
| YEAR | EBIT (undefined AUD) |
|---|---|
| 2027e | 192.9 |
| 2026e | 28.35 |
| 2025e | -20.02 |
| 2024e | -47.13 |
| 2023 | -165.45 |
| 2022 | -55.87 |
| 2021 | 20.55 |
| 2020 | 4.86 |
| 2019 | 52.46 |
| 2018 | 62.72 |
| 2017 | 129.82 |
| 2016 | 58.8 |
| 2015 | 19.4 |
| 2014 | 29.8 |
| 2013 | 11.2 |
| 2012 | 6 |
| 2011 | 2.4 |
| 2010 | 2 |
| 2009 | -4.7 |
| 2008 | -3.4 |
| 2007 | -1.8 |
| 2006 | - |
Mayne Pharma Group Revenue, EBIT, Net Income AU000000MYX0 · A1C821
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Mayne Pharma Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Mayne Pharma Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Mayne Pharma Group’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Mayne Pharma Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Mayne Pharma Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Mayne Pharma Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Mayne Pharma Group’s growth potential.
Mayne Pharma Group Revenue, Profit, and EBIT History
| Date | Mayne Pharma Group Revenue | Mayne Pharma Group EBIT | Mayne Pharma Group Net Income |
|---|---|---|---|
| 2027e | 584.13 M undefined | 192.9 M undefined | 3.57 M undefined |
| 2026e | 490.56 M undefined | 28.35 M undefined | -2.15 M undefined |
| 2025e | 429.91 M undefined | -20.02 M undefined | -20.97 M undefined |
| 2024e | 386.43 M undefined | -47.13 M undefined | -41.93 M undefined |
| 2023 | 190.31 M undefined | -165.45 M undefined | 117.25 M undefined |
| 2022 | 157.61 M undefined | -55.87 M undefined | -281.29 M undefined |
| 2021 | 401.47 M undefined | 20.55 M undefined | -208.42 M undefined |
| 2020 | 457.77 M undefined | 4.86 M undefined | -92.79 M undefined |
| 2019 | 526.22 M undefined | 52.46 M undefined | -279.2 M undefined |
| 2018 | 530.43 M undefined | 62.72 M undefined | -133.98 M undefined |
| 2017 | 572.6 M undefined | 129.82 M undefined | 88.57 M undefined |
| 2016 | 267.28 M undefined | 58.8 M undefined | 37.36 M undefined |
| 2015 | 141.42 M undefined | 19.4 M undefined | 7.76 M undefined |
| 2014 | 143.3 M undefined | 29.8 M undefined | 21.3 M undefined |
| 2013 | 84.1 M undefined | 11.2 M undefined | -2.8 M undefined |
| 2012 | 52.5 M undefined | 6 M undefined | 6.2 M undefined |
| 2011 | 50.1 M undefined | 2.4 M undefined | 1.7 M undefined |
| 2010 | 36.7 M undefined | 2 M undefined | 3.3 M undefined |
| 2009 | 400,000 undefined | -4.7 M undefined | -3.8 M undefined |
| 2008 | 800,000 undefined | -3.4 M undefined | -3.5 M undefined |
| 2007 | 100,000 undefined | -1.8 M undefined | -1.8 M undefined |
| 2006 | 0 undefined | 0 undefined | 0 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2006 | 0 AUD | 0 AUD | 0 AUD |
| 2007 | 100,000 AUD | -1.8 M AUD | -1.8 M AUD |
| 2008 | 800,000 AUD | -3.4 M AUD | -3.5 M AUD |
| 2009 | 400,000 AUD | -4.7 M AUD | -3.8 M AUD |
| 2010 | 36.7 M AUD | 2 M AUD | 3.3 M AUD |
| 2011 | 50.1 M AUD | 2.4 M AUD | 1.7 M AUD |
| 2012 | 52.5 M AUD | 6 M AUD | 6.2 M AUD |
| 2013 | 84.1 M AUD | 11.2 M AUD | -2.8 M AUD |
| 2014 | 143.3 M AUD | 29.8 M AUD | 21.3 M AUD |
| 2015 | 141.42 M AUD | 19.4 M AUD | 7.76 M AUD |
| 2016 | 267.28 M AUD | 58.8 M AUD | 37.36 M AUD |
| 2017 | 572.6 M AUD | 129.82 M AUD | 88.57 M AUD |
| 2018 | 530.43 M AUD | 62.72 M AUD | -133.98 M AUD |
| 2019 | 526.22 M AUD | 52.46 M AUD | -279.2 M AUD |
| 2020 | 457.77 M AUD | 4.86 M AUD | -92.79 M AUD |
| 2021 | 401.47 M AUD | 20.55 M AUD | -208.42 M AUD |
| 2022 | 157.61 M AUD | -55.87 M AUD | -281.29 M AUD |
| 2023 | 190.31 M AUD | -165.45 M AUD | 117.25 M AUD |
| 2024e | 386.43 M AUD | -47.13 M AUD | -41.93 M AUD |
| 2025e | 429.91 M AUD | -20.02 M AUD | -20.97 M AUD |
| 2026e | 490.56 M AUD | 28.35 M AUD | -2.15 M AUD |
| 2027e | 584.13 M AUD | 192.9 M AUD | 3.57 M AUD |
Mayne Pharma Group stock margins AU000000MYX0 · A1C821
The Mayne Pharma Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mayne Pharma Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mayne Pharma Group.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Mayne Pharma Group's sales revenue. A higher gross margin percentage indicates that the Mayne Pharma Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Mayne Pharma Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Mayne Pharma Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Mayne Pharma Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Mayne Pharma Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Mayne Pharma Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Mayne Pharma Group Margin History
| Mayne Pharma Group Gross margin | Mayne Pharma Group Profit margin | Mayne Pharma Group EBIT margin | Mayne Pharma Group Profit margin |
|---|---|---|---|
| 2027e | 47.51 % | 33.02 % | 0.61 % |
| 2026e | 47.51 % | 5.78 % | -0.44 % |
| 2025e | 47.51 % | -4.66 % | -4.88 % |
| 2024e | 47.51 % | -12.2 % | -10.85 % |
| 2023 | 47.51 % | -86.94 % | 61.61 % |
| 2022 | 47.74 % | -35.45 % | -178.47 % |
| 2021 | 45.5 % | 5.12 % | -51.92 % |
| 2020 | 46.38 % | 1.06 % | -20.27 % |
| 2019 | 60.13 % | 9.97 % | -53.06 % |
| 2018 | 53.61 % | 11.82 % | -25.26 % |
| 2017 | 56.82 % | 22.67 % | 15.47 % |
| 2016 | 63.79 % | 22 % | 13.98 % |
| 2015 | 56.56 % | 13.71 % | 5.49 % |
| 2014 | 52.41 % | 20.8 % | 14.86 % |
| 2013 | 47.21 % | 13.32 % | -3.33 % |
| 2012 | 44.19 % | 11.43 % | 11.81 % |
| 2011 | 46.31 % | 4.79 % | 3.39 % |
| 2010 | 47.96 % | 5.45 % | 8.99 % |
| 2009 | 100 % | -1,175 % | -950 % |
| 2008 | 47.51 % | -425 % | -437.5 % |
| 2007 | 47.51 % | -1,800 % | -1,800 % |
| 2006 | 47.51 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2006 | 47.51 % | 0 % | 0 % |
| 2007 | 47.51 % | -1,800 % | -1,800 % |
| 2008 | 47.51 % | -425 % | -437.5 % |
| 2009 | 100 % | -1,175 % | -950 % |
| 2010 | 47.96 % | 5.45 % | 8.99 % |
| 2011 | 46.31 % | 4.79 % | 3.39 % |
| 2012 | 44.19 % | 11.43 % | 11.81 % |
| 2013 | 47.21 % | 13.32 % | -3.33 % |
| 2014 | 52.41 % | 20.8 % | 14.86 % |
| 2015 | 56.56 % | 13.71 % | 5.49 % |
| 2016 | 63.79 % | 22 % | 13.98 % |
| 2017 | 56.82 % | 22.67 % | 15.47 % |
| 2018 | 53.61 % | 11.82 % | -25.26 % |
| 2019 | 60.13 % | 9.97 % | -53.06 % |
| 2020 | 46.38 % | 1.06 % | -20.27 % |
| 2021 | 45.5 % | 5.12 % | -51.92 % |
| 2022 | 47.74 % | -35.45 % | -178.47 % |
| 2023 | 47.51 % | -86.94 % | 61.61 % |
| 2024e | 47.51 % | -12.2 % | -10.85 % |
| 2025e | 47.51 % | -4.66 % | -4.88 % |
| 2026e | 47.51 % | 5.78 % | -0.44 % |
| 2027e | 47.51 % | 33.02 % | 0.61 % |
Mayne Pharma Group Aktienanalyse
What does Mayne Pharma Group do?
Mayne Pharma Group Ltd. is a leading company in the field of pharmaceutical development and production with manufacturing facilities in Australia and the USA. The company is headquartered in Sydney, Australia and employs over 1,100 employees worldwide. The history of Mayne Pharma dates back to 1845 when the company was founded as a manufacturer of herbal medicine. Over the years, the company has evolved and focused on the pharmaceutical industry, eventually being renamed Mayne Nickless Ltd in 1981. In 2000, the company established its subsidiary Mayne Pharma, specializing in the development and production of generic drugs. Through the acquisition of other companies, Mayne Pharma has expanded its product range and expanded into the USA in 2007. Mayne Pharma focuses on the production of generics and specialty pharmaceuticals, which are marketed worldwide through a variety of distribution channels. The company invests heavily in research and development to develop new products and improve existing ones. The goal is to continuously expand the offering and increase market presence. Through the expansion of the product portfolio and the exploration of new markets, Mayne Pharma has gained a strong position in the pharmaceutical industry in recent years. Mayne Pharma is divided into three divisions: generics, specialty pharmaceuticals, and beauty products. The generics division includes a wide range of prescription generic drugs marketed in the USA, Australia, Canada, and other countries. The company is able to produce cost-effective medications to provide affordable drugs to patients worldwide. The specialty pharmaceuticals division focuses on medications for the treatment of diseases such as cancer, pain, and cardiovascular diseases. Mayne Pharma aims to improve treatment outcomes for patients in these areas and has a promising product development pipeline that includes many innovative therapy options. The beauty products division offers a wide range of high-quality skincare products sold worldwide. This includes skin creams, lip care products, and sunscreens. This division is growing steadily and offers great potential, as it operates not only in the healthcare sector but also in the beauty market. Mayne Pharma has a wide range of products, ranging from medications for everyday ailments to life-saving specialty preparations. Key products include: - Doryx: An oral antibiotic therapy for the treatment of mild to moderate acne. - Lonsurf: A cancer-fighting medication that extends the survival time of advanced colorectal cancer patients. - Kapanol: A long-acting opioid for pain relief in patients with severe pain. - Tolsura: An easy-to-use medication for the treatment of fungal infections, particularly suitable for patients who have difficulty swallowing tablets. - Zenavod: A topical medication for the treatment of vaginal infections. - Golden Glow Sunscreen: A high-quality sunscreen with SPF 50+ that prevents skin irritation and sunburn. In conclusion, Mayne Pharma is a proven and innovative company that focuses on the development and production of generics and specialty pharmaceuticals. With its extensive product range and business activities in key international markets, Mayne Pharma has an outstanding reputation in the pharmaceutical industry. Mayne Pharma Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Mayne Pharma Group's EBIT
Mayne Pharma Group's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Mayne Pharma Group's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Mayne Pharma Group's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Mayne Pharma Group’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Mayne Pharma Group Stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Mayne Pharma Group.
How has the EBIT of Mayne Pharma Group developed in recent years?
The EBIT of Mayne Pharma Group has increased by -71.516% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Mayne Pharma Group?
The EBIT of Mayne Pharma Group is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Mayne Pharma Group pay?
Over the past 12 months, Mayne Pharma Group paid a dividend of 0.78 AUD . This corresponds to a dividend yield of about 17.04 %. For the coming 12 months, Mayne Pharma Group is expected to pay a dividend of 0.86 AUD.
What is the dividend yield of Mayne Pharma Group?
The current dividend yield of Mayne Pharma Group is 17.04 %.
When does Mayne Pharma Group pay dividends?
Mayne Pharma Group pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Mayne Pharma Group?
Mayne Pharma Group paid dividends every year for the past 1 years.
What is the dividend of Mayne Pharma Group?
For the upcoming 12 months, dividends amounting to 0.86 AUD are expected. This corresponds to a dividend yield of 18.89 %.
In which sector is Mayne Pharma Group located?
Mayne Pharma Group is assigned to the 'Health' sector.
Wann musste ich die Aktien von Mayne Pharma Group kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Mayne Pharma Group from 1/27/2023 amounting to 0.777 AUD, you needed to have the stock in your portfolio before the ex-date on 1/18/2023.
When did Mayne Pharma Group pay the last dividend?
The last dividend was paid out on 1/27/2023.
What was the dividend of Mayne Pharma Group in the year 2023?
In the year 2023, Mayne Pharma Group distributed 0 AUD as dividends.
In which currency does Mayne Pharma Group pay out the dividend?
The dividends of Mayne Pharma Group are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Mayne Pharma Group
Our stock analysis for Mayne Pharma Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mayne Pharma Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Mayne Pharma Group Revenue
- Mayne Pharma Group Net Income
- Mayne Pharma Group P/E
- Mayne Pharma Group P/S
- Mayne Pharma Group EBIT
- Mayne Pharma Group Dividend
- Mayne Pharma Group Stocks
- Mayne Pharma Group Market capitalization
- Mayne Pharma Group Debt
- Mayne Pharma Group Liabilities
- Mayne Pharma Group Equity
- Mayne Pharma Group AAQS
- Mayne Pharma Group Employees
- Mayne Pharma Group ROE
- Mayne Pharma Group ROA
- Mayne Pharma Group ROCE
